Up to 80% of men with Prostate-Specific Antigen (PSA) screen-detected prostate cancer are overdiagnosed, that is, their cancer would never have caused any symptoms. Overdiagnosis would matter less if treatment had no adverse effects. Ideally treatment should be restricted to those who need it. Active surveillance aims to individualize the management of early prostate cancer by selecting only those men with significant cancers for curative treatment.
PRIAS (Prostate cancer Research International: Active Surveillance) presents a program in which selected men with early prostate cancer are managed by a protocolized follow-up strategy.